KNSA logo

Kiniksa Pharmaceuticals (KNSA) EBITDA

annual EBITDA:

-$43.92M-$21.07M(-92.17%)
December 31, 2024

Summary

  • As of today (May 29, 2025), KNSA annual EBITDA is -$43.92 million, with the most recent change of -$21.07 million (-92.17%) on December 31, 2024.
  • During the last 3 years, KNSA annual EBITDA has risen by +$110.36 million (+71.53%).
  • KNSA annual EBITDA is now -460.75% below its all-time high of $12.18 million, reached on December 31, 2022.

Performance

KNSA EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKNSAincome statement metrics

quarterly EBITDA:

$13.62M+$32.52M(+172.05%)
March 31, 2025

Summary

  • As of today (May 29, 2025), KNSA quarterly EBITDA is $13.62 million, with the most recent change of +$32.52 million (+172.05%) on March 31, 2025.
  • Over the past year, KNSA quarterly EBITDA has increased by +$29.69 million (+184.70%).
  • KNSA quarterly EBITDA is now -70.97% below its all-time high of $46.91 million, reached on September 30, 2022.

Performance

KNSA quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKNSAincome statement metrics

TTM EBITDA:

-$14.23M+$29.69M(+67.61%)
March 31, 2025

Summary

  • As of today (May 29, 2025), KNSA TTM EBITDA is -$14.23 million, with the most recent change of +$29.69 million (+67.61%) on March 31, 2025.
  • Over the past year, KNSA TTM EBITDA has increased by +$14.10 million (+49.78%).
  • KNSA TTM EBITDA is now -135.22% below its all-time high of $40.40 million, reached on June 30, 2023.

Performance

KNSA TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKNSAincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

KNSA EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-92.2%+184.7%+49.8%
3 y3 years+71.5%+160.1%+88.9%
5 y5 years+73.8%+147.3%+89.0%

KNSA EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-460.8%+71.5%-71.0%+160.1%-135.2%+88.9%
5 y5-year-460.8%+73.8%-71.0%+126.0%-135.2%+92.3%
alltimeall time-460.8%+73.8%-71.0%+120.3%-135.2%+92.3%

KNSA EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
$13.62M(-172.1%)
-$14.23M(-67.6%)
Dec 2024
-$43.92M(+92.2%)
-$18.90M(+104.1%)
-$43.92M(+80.0%)
Sep 2024
-
-$9.26M(-3058.1%)
-$24.40M(-4.2%)
Jun 2024
-
$313.00K(-101.9%)
-$25.47M(-10.1%)
Mar 2024
-
-$16.08M(-2688.7%)
-$28.33M(+24.0%)
Dec 2023
-$22.86M(-287.7%)
$621.00K(-106.0%)
-$22.86M(+35.8%)
Sep 2023
-
-$10.32M(+304.5%)
-$16.83M(-141.6%)
Jun 2023
-
-$2.55M(-75.9%)
$40.40M(+66.7%)
Mar 2023
-
-$10.60M(-259.4%)
$24.24M(+99.1%)
Dec 2022
$12.18M(-107.9%)
$6.65M(-85.8%)
$12.18M(-140.7%)
Sep 2022
-
$46.91M(-350.6%)
-$29.94M(-72.0%)
Jun 2022
-
-$18.72M(-17.4%)
-$106.85M(-16.5%)
Mar 2022
-
-$22.66M(-36.1%)
-$127.97M(-17.1%)
Dec 2021
-$154.28M(-0.4%)
-$35.46M(+18.2%)
-$154.28M(-9.9%)
Sep 2021
-
-$30.01M(-24.7%)
-$171.15M(-6.8%)
Jun 2021
-
-$39.84M(-18.6%)
-$183.71M(+4.9%)
Mar 2021
-
-$48.97M(-6.4%)
-$175.14M(+13.0%)
DateAnnualQuarterlyTTM
Dec 2020
-$154.96M(-7.7%)
-$52.33M(+22.9%)
-$154.96M(+15.1%)
Sep 2020
-
-$42.57M(+36.2%)
-$134.64M(+10.4%)
Jun 2020
-
-$31.27M(+8.6%)
-$122.00M(-5.8%)
Mar 2020
-
-$28.79M(-10.1%)
-$129.51M(-22.9%)
Dec 2019
-$167.90M(+55.6%)
-$32.02M(+7.0%)
-$167.90M(-6.6%)
Sep 2019
-
-$29.92M(-22.8%)
-$179.76M(+2.1%)
Jun 2019
-
-$38.78M(-42.3%)
-$175.99M(+10.9%)
Mar 2019
-
-$67.18M(+53.1%)
-$158.72M(+47.1%)
Dec 2018
-$107.87M(+65.0%)
-$43.88M(+67.8%)
-$107.88M(+11.6%)
Sep 2018
-
-$26.15M(+21.5%)
-$96.70M(+11.4%)
Jun 2018
-
-$21.52M(+31.7%)
-$86.79M(+13.2%)
Mar 2018
-
-$16.33M(-50.1%)
-$76.66M(+17.3%)
Dec 2017
-$65.37M(+172.6%)
-$32.70M(+101.4%)
-$65.37M(+100.1%)
Sep 2017
-
-$16.24M(+42.6%)
-$32.67M(+98.9%)
Jun 2017
-
-$11.39M(+125.8%)
-$16.43M(+225.8%)
Mar 2017
-
-$5.04M
-$5.04M
Dec 2016
-$23.98M
-
-

FAQ

  • What is Kiniksa Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Kiniksa Pharmaceuticals?
  • What is Kiniksa Pharmaceuticals annual EBITDA year-on-year change?
  • What is Kiniksa Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Kiniksa Pharmaceuticals?
  • What is Kiniksa Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Kiniksa Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Kiniksa Pharmaceuticals?
  • What is Kiniksa Pharmaceuticals TTM EBITDA year-on-year change?

What is Kiniksa Pharmaceuticals annual EBITDA?

The current annual EBITDA of KNSA is -$43.92M

What is the all time high annual EBITDA for Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals all-time high annual EBITDA is $12.18M

What is Kiniksa Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, KNSA annual EBITDA has changed by -$21.07M (-92.17%)

What is Kiniksa Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of KNSA is $13.62M

What is the all time high quarterly EBITDA for Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals all-time high quarterly EBITDA is $46.91M

What is Kiniksa Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, KNSA quarterly EBITDA has changed by +$29.69M (+184.70%)

What is Kiniksa Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of KNSA is -$14.23M

What is the all time high TTM EBITDA for Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals all-time high TTM EBITDA is $40.40M

What is Kiniksa Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, KNSA TTM EBITDA has changed by +$14.10M (+49.78%)
On this page